As long­time CMO ex­its, Karyopharm taps Big Phar­ma vets to steer can­cer drug fran­chise

As Richard Paul­son con­tin­ues to make a case for the Xpovio fran­chise, he will be sur­round­ing him­self with a new clin­i­cal team at Karyopharm.

The biotech re­vealed Tues­day that ex­ec­u­tive vice pres­i­dent and chief med­ical of­fi­cer Jatin Shah de­parts for “oth­er pro­fes­sion­al op­por­tu­ni­ties.” While CEO Paul­son looks for Shah’s re­place­ment, he has re­cruit­ed two Big Phar­ma vets to take up key posts on the team: Pa­tri­cia Jud­son, who led women’s on­col­o­gy at both Glax­o­SmithK­line and As­traZeneca, will be­come SVP of med­ical strat­e­gy; and Stu­art Poul­ton, for­mer­ly of Ab­b­Vie, Am­gen and Eli Lil­ly, has been ap­point­ed SVP of strat­e­gy and port­fo­lio man­age­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER